Bristol-Myers’s Opdivo (nivolumab) Receives FDA Priority Review for 2L+ Patients with SCLC in ~20 yrs

 Bristol-Myers’s Opdivo (nivolumab) Receives FDA Priority Review for 2L+ Patients with SCLC in ~20 yrs

BMS’s Sprycel (dasatinib) sBLA Receives Positive Response from the US FDA

Shots:
  • Approval is based ongoing Ph 1/2 CheckMate-032, study is assessing 245 patients in two arms Opdivo vs platinum based therapy
  • CheckMater-032 Results:  ORR:12% (13/109); PR: 11% (12/109); CR: 0.9% (1/109); mDOR: 17.9 mos; SAE: 45%
  • Approved dose for Opdivo for SCLC is 240mg IV Q2W until disease progression or unacceptable toxicity
Click here to read full press release/ article | Ref: Bristol-Myers | Image: NYSE

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post